SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company dedicated to the discovery and development of novel cancer immunotherapies and targeted oncology treatments. The company's pipeline is anchored by its lead product candidate, galinpepimut-S (GPS), a peptide immunotherapy licensed from Memorial Sloan Kettering Cancer Center. GPS targets the Wilms tumor 1 (WT1) protein, an antigen present in an array of tumor types, and is currently in a pivotal Phase 3 REGAL clinical trial for acute myeloid leukemia (AML). Additionally, SELLAS is developing SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor, which is being evaluated in Phase 2 trials for AML and peripheral T-cell lymphoma. As a clinical-stage company, SELLAS does not currently generate commercial product revenue and relies on capital raises, such as equity offerings and warrant exercises, to fund its research and development activities. The company operates primarily in the United States and collaborates with various research institutions and pharmaceutical partners to advance its clinical programs.
